Faculty

Institution

Unit

Venue

Max Kullberg

Assistant Professor

University of Alaska Anchorage

Affiliations

College of Health

Medical School

Department Of Family And Community Medicine

University of Alaska Anchorage

Max Kullberg is currently serving as a College Of Health Assistant Professor at University of Alaska Anchorage.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Max Kullberg

University of Alaska Anchorage

Assistant Professor

You can click a keyword to filter the displayed items

cell biology immunology cellular therapy immunotherapy therapeutic targets cancer cells immune responses tumor targeting drug targeting cancer immunotherapy immunomodulation controlled release molecular cancer oncogenes biomolecular engineering lipids nanomedicine drug delivery breast cancer cell death experimental medicine breast oncology anti-cancer agents immunologic mechanisms biomedical engineering biological macromolecules biomolecules pharmaceutics cell transplantation nano-drug delivery phagocytes immune mediators therapeutic vaccines complement c3-targeted liposomes leukemia medicinal research cancer biology lipid movement pharmaceutical nanotechnology therapeutic nanomaterials granulocyte innate immune system cellular immune responses novel therapies cancer immunosurveillance bleomycin immunoliposomes linked listeriolysin o her-2-targeting thermosensitive liposomes complement c3 granulocytic myeloid suppressor cells targeted liposomes human macrophages complement c3-dependent uptake toll-like receptor agonists immune cells tumor growth intratumoral delivery complement c3-bound liposomes trastuzumab-targeted gene delivery

Notable Scholarly Works

Notable Federal Grants

Collaborators

C3-Liposome Delivery of Muc1 Peptide and Tlr Agonists Enhances Adaptive Immunity and Results in Sex-Based Tumor Growth Differences. Pharmaceutics (2025)

immunomodulationcancer immunotherapycell biologycancer immunosurveillancetherapeutic targetstumor biologycellular therapycancer researchimmunotherapytumor microenvironmentimmune responsesmolecular cancerimmunologyc3-liposome deliverycancer cellsoncogenesdrug targetingmuc1 peptidetherapeutic vaccines

Immunotherapy Platform That Conjugates Antigen to Complement C3-Targeted Liposomes Induces a Robust Adaptive Immune Response. International Journal of Molecular Sciences (2025)

immunomodulationimmune responsesvaccinescellular therapyimmunologic mechanismsimmunotherapy platformcell biologyimmunotherapyimmunologycell transplantationtherapeutic vaccinescomplement c3-targeted liposomes

Enhancing T Cell and Antibody Response in Mucin-1 Transgenic Mice Through Co-Delivery of Tumor-Associated Mucin-1 Antigen and Tlr Agonists in C3-Liposomes. Pharmaceutics (2023)

immunomodulationcancer immunotherapyimmune responsescellular therapymucin-1 transgenic micecell biologycancer cellsimmunotherapyt cellimmunologyexperimental medicinetumor-associated mucin-1 antigencellular immune responses

Delivery of Toll-Like Receptor Agonists by Complement C3-Targeted Liposomes Activates Immune Cells and Reduces Tumour Growth. Journal of drug targeting (2021)

immunomodulationcancer immunotherapyimmune responsescellular therapyimmunologic mechanismscell biologycancer cellsimmunotherapycomplement c3-targeted liposomesimmunologytoll-like receptor agoniststherapeutic targetsimmune cellscell deathimmune mediators

Inhibiting Stat3 and Activating Tlr Against Tumors With Opss Liposomes, Curcumin, and Tlr Agonists. Journal of Student Research (2021)

cancer immunotherapyanti-cancer agentsopss liposomesmolecular cancertlr agonistscell biologycell signalingcancer cellsimmunologypharmacologydrug targetingtherapeutic targetstumor targetingexperimental medicine

Liposome Delivery of Natural Stat3 Inhibitors for the Treatment of Cancer. (2019)

anti-cancer agentsnovel therapiesliposome deliverycell biologymedicinal researchnatural stat3 inhibitorspharmacologydrug targetingtherapeutic targetslipidsnanomedicinetumor targetingcontrolled releasedrug discoverypharmaceuticsdrug delivery

Intratumoral Delivery of Antigen With Complement C3-Bound Liposomes Reduces Tumor Growth in Mice. Nanomedicine Nanotechnology Biology and Medicine (2018)

immunomodulationtumor biologyimmune responsescellular therapycomplement c3-bound liposomescell biologyimmunotherapyimmunologycell transplantationtumor targetingtumor growthintratumoral delivery

Complement C3-Dependent Uptake of Targeted Liposomes Into Human Macrophages, B Cells, Dendritic Cells, Neutrophils, and Mdscs. International Journal of Nanomedicine (2017)

immune responsescellular therapyimmunologic mechanismsinflammationhuman macrophagescomplement c3-dependent uptakephagocytestargeted liposomescell biologyimmunotherapyimmunologyinnate immune systemcell deathimmune mediators

Trastuzumab-Targeted Gene Delivery to Her2-Overexpressing Breast Cancer Cells. Cancer Gene Therapy (2016)

cellular therapymolecular cancertrastuzumab-targeted gene deliverycell biologycancer cellsbreast oncologyoncogenesdrug targetingtherapeutic targetstumor targetinggene therapybreast cancer

Complement C3 Mediated Targeting of Liposomes to Granulocytic Myeloid Derived Suppressor Cells. Nanomedicine Nanotechnology Biology and Medicine (2015)

suppressor cellsimmune responsescellular therapycomplement c3inflammationphagocytescell biologyleukemiagranulocyteimmunotherapyimmunologygranulocytic myeloidexperimental medicinecell deathpathology

1
2
10 / page

Max Kullberg

Assistant Professor

University of Alaska Anchorage

Affiliations

College of Health

Medical School

Department Of Family And Community Medicine

University of Alaska Anchorage

Max Kullberg is currently serving as a College Of Health Assistant Professor at University of Alaska Anchorage.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Max Kullberg

University of Alaska Anchorage

Assistant Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

C3-Liposome Delivery of Muc1 Peptide and Tlr Agonists Enhances Adaptive Immunity and Results in Sex-Based Tumor Growth Differences. Pharmaceutics (2025)

Immunotherapy Platform That Conjugates Antigen to Complement C3-Targeted Liposomes Induces a Robust Adaptive Immune Response. International Journal of Molecular Sciences (2025)

Enhancing T Cell and Antibody Response in Mucin-1 Transgenic Mice Through Co-Delivery of Tumor-Associated Mucin-1 Antigen and Tlr Agonists in C3-Liposomes. Pharmaceutics (2023)

Delivery of Toll-Like Receptor Agonists by Complement C3-Targeted Liposomes Activates Immune Cells and Reduces Tumour Growth. Journal of drug targeting (2021)

Inhibiting Stat3 and Activating Tlr Against Tumors With Opss Liposomes, Curcumin, and Tlr Agonists. Journal of Student Research (2021)

Liposome Delivery of Natural Stat3 Inhibitors for the Treatment of Cancer. (2019)

Intratumoral Delivery of Antigen With Complement C3-Bound Liposomes Reduces Tumor Growth in Mice. Nanomedicine Nanotechnology Biology and Medicine (2018)

immunomodulationtumor biologyimmune responsescellular therapycomplement c3-bound liposomescell biologyimmunotherapyimmunologycell transplantationtumor targetingtumor growthintratumoral delivery

Complement C3-Dependent Uptake of Targeted Liposomes Into Human Macrophages, B Cells, Dendritic Cells, Neutrophils, and Mdscs. International Journal of Nanomedicine (2017)

Trastuzumab-Targeted Gene Delivery to Her2-Overexpressing Breast Cancer Cells. Cancer Gene Therapy (2016)

cellular therapymolecular cancertrastuzumab-targeted gene deliverycell biologycancer cellsbreast oncologyoncogenesdrug targetingtherapeutic targetstumor targetinggene therapybreast cancer

Complement C3 Mediated Targeting of Liposomes to Granulocytic Myeloid Derived Suppressor Cells. Nanomedicine Nanotechnology Biology and Medicine (2015)

suppressor cellsimmune responsescellular therapycomplement c3inflammationphagocytescell biologyleukemiagranulocyteimmunotherapyimmunologygranulocytic myeloidexperimental medicinecell deathpathology

1
2
10 / page